COVAX purchases new 140m doses of Pfizer-BioNTech, AstraZeneca/Oxford vaccines for poor countries
London, Jan. 23, 2021 (AltAfrica)-COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, has announced the signing of an advance purchase agreement for new 140 million doses of vaccines
Of the new purchase agreement, 40 million doses will come from the Pfizer-BioNTech vaccine candidate, which has already received WHO emergency use listing.
The balance of 100 million doses will come via an existing agreement with Serum Institute of India (SII) for the AstraZeneca/Oxford University-developed vaccine manufactured by SII.
Covax explained that majority of the first 100 million doses are earmarked for delivery in the first quarter of the year, pending WHO Emergency Use Listing.
We are proud to announce that Pfizer & BioNTech have signed an agreement with #COVAX for up to 40M doses of our #COVID19 vaccine. This is an important step in the fight against the virus – a fight that will only end when we have #OneWorldProtected. @who @gavi @cepivaccines— Pfizer Inc. (@pfizer) January 22, 2021
The WHO review process, which is currently underway, follows approval for restricted use in emergency situations by the Drugs Controller General of India earlier this month, and is a critical aspect of ensuring that any vaccine procured through COVAX is fully quality assured for international use.
According to the latest WHO update, a decision on this vaccine candidate is anticipated by the middle of February.
COVAX also anticipates that, via an existing agreement with AstraZeneca, at least 50 million further doses of the AstraZeneca/Oxford vaccine will be available for delivery to COVAX participants in Q1 2021, pending emergency use listing by WHO of the COVAX-specific manufacturing network for these doses.
A decision on this candidate is also anticipated by WHO in February.
“Today marks another milestone for COVAX: pending regulatory approval for the AstraZeneca/Oxford candidate and pending the successful conclusion of the supply agreement for the Pfizer-BioNTech vaccine, we anticipate being able to begin deliveries of life-saving COVID-19 vaccines by the end of February.
“This is not just significant for COVAX, it is a major step forward for equitable access to vaccines, and an essential part of the global effort to beat this pandemic. We will only be safe anywhere if we are safe everywhere,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance, which leads COVAX procurement and delivery.
Preparations, led by WHO, UNICEF and Gavi, are already well under way for COVAX to deliver vaccines to economies eligible for support via the COVAX AMC, with Gavi making US$ 150 million available from its core funding as initial, catalytic support for preparedness and delivery.
“The urgent and equitable rollout of vaccines is not just a moral imperative, it’s also a health security, strategic and economic imperative,” said Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization. “This agreement with Pfizer will help to enable COVAX to save lives, stabilize health systems and drive the global economic recovery.”
Building on the work of the past months supporting country readiness efforts, a “Country Readiness Portal” will be launched by WHO this month, which will allow AMC participants to submit final national deployment and vaccination plans (NDVPs). This is a vital step before allocations can be made, to ensure that delivered doses are able to be effectively deployed and to identify where, if necessary, further support is needed.
“These purchase agreements open the door for these lifesaving vaccines to become available to people in the most vulnerable countries,” said UNICEF Executive Director Henrietta Fore. “But at the same time we are securing vaccines we must also ensure that countries are ready to receive them, deploy them, and build trust in them.”
The COVAX Facility intends to provide all 190 participating economies with an indicative allocation of doses by the end of this month.
This indicative allocation will provide interim guidance to participants – offering a minimum planning scenario to enable preparations for the final allocation of the number of doses each participant will receive in the first rounds of vaccine distribution.